Combination therapies with inhaled corticosteroids (ICS) and either long-acting β2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.
Baiardini, I., Braido, F., Giardini, A., Majani, G., Cacciola, C., Rogaku, A. et al. (2006) Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol16: 218-223.
2.
Bijl-Hofland, I.D., Cloosterman, S.G., Folgering, H.T., Akkermans, R.P. and van Schayck, C.P. (1999) Relation of the perception of airway obstruction to the severity of asthma. Thorax54: 15-19.
3.
Bjermer, L., Bisgaard, H., Bousquet, J., Fabbri, L.M., Greening, A.P., Haahtela, T. et al. (2003) Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ327: 1-6.
4.
Bousquet, J., Ben-Joseph, R., Messonnier, M., Alemao, E. and Gould, A.L. (2002) A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther24: 1-20.
5.
Bousquet, J., Gaugris, S., Kocevar, V.S., Zhang, Q., Yin, D.D., Polos, P.G. et al. (2005) Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy35: 723-727.
6.
Bousquet, J., Van, C.P. and Khaltaev, N. (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol108: S147-S334.
7.
Busse, W.W., Casale, T.B., Dykewicz, M.S., Meltzer, E.O., Bird, S.R., Hustad, C.M. et al. (2006) Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity . Ann Allergy Asthma Immunol96: 60-68.
8.
Chalmers, G.W., Macleod, K.J., Little, S.A., Thomson, L.J., McSharry, C.P. and Thomson, N.C. (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax57: 226-230.
9.
Chetta, A., Gerra, G., Foresi, A., Zaimovic, A., Del, D.M., Chittolini, B. et al. (1998) Personality profiles and breathlessness perception in outpatients with different gradings of asthma. Am J Respir Crit Care Med157: 116-122.
10.
Corren, J. (1997) Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol99: S781-S786.
11.
Currie, G.P., Lee, D.K., Haggart, K., Bates, C.E. and Lipworth, B.J. (2003) Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med167: 1232-1238.
12.
Currie, G.P. and Lipworth, B.J. (2002) Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest122: 146-150.
13.
D'Urzo, A.D. (2005) CONtrol Centered Patient Treatment (CONCEPT). Clin Ther27: 1312-1315.
14.
Ducharme, F.M., Lasserson, T.J. and Cates, C.J. (2006) Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev: CD003137.
15.
Edelman, J.M., Turpin, J.A., Bronsky, E.A., Grossman, J., Kemp, J.P., Ghannam, A.F. et al. (2000) Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med132: 97-104.
16.
Fauler, J. and Frolich, J.C. (1997) Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest27: 43-47.
17.
Fish, J.E., Israel, E., Murray, J.J., Emmett, A., Boone, R.,Yancey, S.W. et al. (2001) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest120: 423-430.
18.
FitzGerald, J.M., Boulet, L.P. and Follows, R.M. (2005) The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther27: 393-406.
19.
FitzGerald, J.M., Sears, M.R., Boulet, L.P., Becker, A.B., McIvor, A.R., Ernst, P. et al. (2003) Adjustable maintenance dosing with budesonide/ formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J10: 427-434.
20.
GINA - The Global Strategy for Asthma Management and Prevention 2006. Available at http://www.ginasthma.com/GuidelinesResources.asp . Accessed 12 March 2008.
21.
Greening, A.P., Ind, P.W., Northfield, M. and Shaw, G. (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet344: 219-224.
22.
Herland, K., Akselsen, J.P., Skjonsberg, O.H. and Bjermer, L. (2005) How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med99: 11-19.
23.
Horne, R., Price, D., Cleland, J., Costa, R., Covey, D., Gruffydd-Jones, K. et al. (2007) Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med7: 8.
24.
Jonasson, G., Carlsen, K.H. and Mowinckel, P. (2000) Asthma drug adherence in a long term clinical trial . Arch Dis Child83: 330-333.
25.
Kerstjens, H.A., Overbeek, S.E., Schouten, J.P., Brand, P.L. and Postma, D.S. (1993) Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J6: 868-876.
26.
Kuna, P., Peters, M.J., Manjra, A.I., Jorup, C., Naya, I.P., Martinez-Jimenez, N.E. et al. (2007) Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract61: 725-736.
27.
Laforest, L., Van, G.E., Devouassoux, G., Osman, L.M., Brice, K., Massol, J. et al. (2007) Asthmatic patients' poor awareness of inadequate disease control: a pharmacy-based survey. Ann Allergy Asthma Immunol98: 146-152.
28.
Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I. et al. (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med160: 1862-1868.
29.
Lazarus, S.C., Boushey, H.A., Fahy, J.V., Chinchilli, V.M., Lemanske Jr, R.F. , Sorkness, C.A. et al. (2001) Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA285: 2583-2593.
30.
Lazarus, S.C., Chinchilli, V.M., Rollings, N.J., Boushey, H.A., Cherniack, R., Craig, T.J. et al. (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med175: 783-790.
31.
Leff, J.A., Busse, W.W., Pearlman, D., Bronsky, E.A., Kemp, J., Hendeles, L. et al. (1998) Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction . N Engl J Med339: 147-152.
Lipworth, B.J. and Jackson, C.M. (2002) Bronchodilator reversibility to albuterol predicts bronchodilator response to salmeterol. Chest121: 1382.
34.
McGavin, J.K., Goa, K.L. and Jarvis, B. (2001) Inhaled budesonide/formoterol combination. Drugs61: 71-78.
35.
Mcivor, R.A., Pizzichini, E., Turner, M.O., Hussack, P., Hargreave, F.E. and Sears, M.R. (1998) Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med158: 924-930.
36.
Nelson, H.S., Busse, W.W., Kerwin, E., Church, N., Emmett, A., Rickard, K. et al. (2000) Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol106: 1088-1095.
37.
Nelson, H.S., Weiss, S.T., Bleecker, E.R., Yancey, S.W., Dorinsky, P.M.; SMART Study Group. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest129: 15-26.
38.
Nih/Nhlbi (2007) Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol120: S94-138.
39.
O'Brien, K. and Bukstein, D. (2001) What is "more effective asthma control"? J Allergy Clin Immunol107: 1107-1109.
40.
O'Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu,Y. et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med171: 129-136.
41.
Pauwels, R.A., Lofdahl, C.G., Postma, D.S., Tattersfield, A.E., O'Byrne, P., Barnes, P.J. et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med337: 1405-1411.
42.
Pedersen, B., Dahl, R., Karlstrom, R., Peterson, C.G. and Venge, P. (1996) Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med153: 1519-1529.
43.
Philip, G., Nayak, A.S., Berger, W.E., Leynadier, F., Vrijens, F., Dass, S.B. et al. (2004) The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin20: 1549-1558.
44.
Pizzichini, E., Leff, J.A., Reiss, T.F., Hendeles, L., Boulet, L.P., Wei, L.X. et al. (1999) Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J14: 12-18.
45.
Price, D.B., Hernandez, D., Magyar, P., Fiterman, J., Beeh, K.M., James, I.G. et al. (2003) Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax58: 211-216.
46.
Rabe, K.F., Atienza, T., Magyar, P., Larsson, P., Jorup, C. and Lalloo, U.G. (2006a) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet368: 744-753.
47.
Rabe, K.F., Pizzichini, E., Stallberg, B., Romero, S., Balanzat, A.M., Atienza, T. et al. (2006b) Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest129: 246-256.
48.
Ramage, L., Lipworth, B.J., Ingram, C.G., Cree, I.A. and Dhillon, D.P. (1994) Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med88: 363-368.
49.
Rau, J.L. (2005) Determinants of patient adherence to an aerosol regimen. Respir Care50: 1346-1356.
50.
Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. and Edwards, T.B. (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic
51.
asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med158: 1213-1220.
52.
Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centanni, S. et al. (2004) Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin20: 1403-1418.
53.
Simons, F.E., Villa, J.R., Lee, B.W., Teper, A.M., Lyttle, B., Aristizabal, G. et al. (2001) Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr138: 694-698.
54.
Stallberg, B., Olsson, P., Jorgensen, L.A., Lindarck, N. and Ekstrom, T. (2003) Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract57: 656-661.
55.
Storms, W., Chervinsky, P., Ghannam, A.F., Bird, S., Hustad, C.M. and Edelman, J.M. (2004) A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge . Respir Med98: 1051-1062.
56.
Tattersfield, A.E., Postma, D.S., Barnes, P.J., Svensson, K., Bauer, C.A., O'Byrne, P.M. et al. (1999) Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med160: 594-599.
57.
Thomas, M., Leather, D. and Price, D. (2006) High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. Prim Care Respir J15: 166-172.
58.
Thomson, N.C., Chaudhuri, R. and Livingston, E. (2004) Asthma and cigarette smoking. Eur Respir J24: 822-833.
59.
Vaquerizo, M.J., Casan, P., Castillo, J., Perpina, M., Sanchis, J., Sobradillo, V. et al. (2003) Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax58: 204-210.
60.
Villaran, C., O'Neill, S.J., Helbling, A., van Noord, J.A., Lee, T.H., Chuchalin, A.G. et al. (1999) Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol104: 547-553.
61.
Virchow, J.C. and Bachert, C. (2006) Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med100: 1952-1959.
62.
Vogelmeier, C., D'Urzo, A., Pauwels, R., Merino, J.M., Jaspal, M., Boutet, S. et al. (2005) Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J26: 819-828.
63.
Williams, L.K., Pladevall, M., Xi, H., Peterson, E.L., Joseph, C., Lafata, J.E. et al. (2004) Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol114: 1288-1293.
64.
Yates, D.H., Kharitonov, S.A. and Barnes, P.J. (1996) An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med154: 1603-1607.
